Gene: ATP2B4

493
ATP2B2|MXRA1|PMCA4|PMCA4b|PMCA4x
ATPase plasma membrane Ca2+ transporting 4
protein-coding
1q32.1
Ensembl:ENSG00000058668 MIM:108732 Vega:OTTHUMG00000035906 UniprotKB:P23634
NG_029589.1
SNP Mapped
0   ANCO-SNPs
CD|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.166e-2 (AD)  8.410e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AP1G10.942
RALGAPB0.938
XPO70.937
PUM10.932
COPA0.93
TMEM1310.929
NMT10.928
DHX330.927
KAT70.926
KPNA60.926

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.612
OR4F29-0.562
SH2D1A-0.308
CSAG1-0.293
KLRB1-0.288
TFPI2-0.288
RAI14-0.287
ASB4-0.286
MTRNR2L6-0.285
C9orf153-0.281

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of ATP2B4 mRNA"23196670
C5830744,4'-hexafluorisopropylidene diphenol"4,4'-hexafluorisopropylidene diphenol results in increased expression of ATP2B4 mRNA"27567155
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of ATP2B4 mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of ATP2B4 gene27153756
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of ATP2B4 mRNA21298039
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ATP2B4 mRNA16483693
D001151ArsenicArsenic affects the expression of ATP2B4 mRNA18414638
D001280AtrazineAtrazine results in increased expression of ATP2B4 mRNA22378314
D001280AtrazineAtrazine affects the expression of ATP2B4 mRNA26476475
D001280Atrazinelycopene inhibits the reaction [Atrazine affects the expression of ATP2B4 mRNA]26476475
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ATP2B4 mRNA26001963
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ATP2B4 mRNA20064835
D004958Estradiol[bisphenol A co-treated with Estradiol] results in decreased expression of ATP2B4 mRNA26496021
C006780bisphenol Abisphenol A affects the expression of ATP2B4 mRNA21786754
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in decreased expression of ATP2B4 mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of ATP2B4 mRNA25181051
C006780bisphenol Abisphenol A inhibits the reaction [Triiodothyronine results in increased expression of ATP2B4 mRNA]19228888
D002118CalciumATP2B4 protein results in increased export of Calcium16452157
D002118Calciumcaloxin 1b1 inhibits the reaction [ATP2B4 protein results in increased export of Calcium]16452157
C510327caloxin 1b1caloxin 1b1 inhibits the reaction [ATP2B4 protein results in increased export of Calcium]16452157
D000068579CelecoxibCelecoxib results in decreased expression of ATP2B4 mRNA28201806
D004390ChlorpyrifosChlorpyrifos results in decreased expression of ATP2B4 mRNA18668222
C018021cobaltous chloridecobaltous chloride results in increased expression of ATP2B4 mRNA19376846
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of ATP2B4 mRNA20971185
D016572CyclosporineCyclosporine results in decreased expression of ATP2B4 mRNA25562108
D016047Zalcitabine"[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ATP2B4 mRNA"18606552
C014347decitabinedecitabine affects the expression of ATP2B4 mRNA23300844
D003703DemecolcineDemecolcine results in increased expression of ATP2B4 mRNA23649840
D003907DexamethasoneDexamethasone results in increased expression of ATP2B4 mRNA25047013
D002945CisplatinCisplatin affects the expression of ATP2B4 mRNA23300844
C000944dicrotophosdicrotophos results in increased expression of ATP2B4 mRNA28302478
D004147DioxinsDioxins affects the expression of ATP2B4 mRNA20463971
C012301domoic aciddomoic acid results in increased expression of ATP2B4 mRNA18936300
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of ATP2B4 mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B4 mRNA22079256
D000431EthanolEthanol results in decreased expression of ATP2B4 mRNA29018328
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of ATP2B4 mRNA29097150
D011345FenofibrateFenofibrate results in increased expression of ATP2B4 mRNA25572481
D005419FlavonoidsFlavonoids results in decreased expression of ATP2B4 mRNA18035473
D005557FormaldehydeFormaldehyde results in increased expression of ATP2B4 mRNA23649840
C514793gp120 protein, Human immunodeficiency virus 1"[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ATP2B4 mRNA"18606552
C051890irinotecanATP2B4 protein results in decreased susceptibility to irinotecan16734730
D007657Ketone BodiesKetone Bodies results in decreased expression of ATP2B4 mRNA16807920
D007854LeadLead affects the splicing of ATP2B4 mRNA28903495
C015329lycopenelycopene inhibits the reaction [Atrazine affects the expression of ATP2B4 mRNA]26476475
D017258Medroxyprogesterone AcetateMedroxyprogesterone Acetate results in decreased expression of ATP2B4 mRNA20843944
D008627Mercuric ChlorideMercuric Chloride affects the expression of ATP2B4 mRNA20353558
D008727MethotrexateMethotrexate results in increased expression of ATP2B4 mRNA21678067
C008493methylselenic acidmethylselenic acid results in increased expression of ATP2B4 mRNA18548127
C029938nickel sulfatenickel sulfate results in decreased expression of ATP2B4 mRNA22714537
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of ATP2B4 mRNA20971185
C558013NSC 689534NSC 689534 results in increased expression of ATP2B4 mRNA20971185
D010100OxygenOxygen deficiency results in increased expression of ATP2B4 mRNA24205000
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA"25510870
D010416PentachlorophenolPentachlorophenol results in increased expression of ATP2B4 mRNA24642059
D010656PhenylephrineATP2B4 protein results in increased susceptibility to Phenylephrine12933703
D010710PhosphatesPhosphates affects the expression of ATP2B4 mRNA16490722
C006253pirinixic acidpirinixic acid results in increased expression of ATP2B4 mRNA12832660
D010936Plant ExtractsPlant Extracts results in increased expression of ATP2B4 mRNA22222932
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B4 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of ATP2B4 mRNA22079256
D011374ProgesteroneProgesterone results in decreased expression of ATP2B4 mRNA18070364
D011441PropylthiouracilPropylthiouracil results in increased expression of ATP2B4 mRNA24780913
D015237DinoprostATP2B4 protein results in increased susceptibility to Dinoprost12933703
C502851quinocetonequinocetone results in increased expression of ATP2B4 mRNA27046791
D015474IsotretinoinIsotretinoin results in increased expression of ATP2B4 mRNA20436886
C089730rosiglitazonerosiglitazone results in increased expression of ATP2B4 mRNA25572481
D012643SeleniumSelenium results in increased expression of ATP2B4 mRNA19244175
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ATP2B4 mRNA25895662
C009277sodium arsenatesodium arsenate results in increased expression of ATP2B4 mRNA21795629
D014284Triiodothyroninebisphenol A inhibits the reaction [Triiodothyronine results in increased expression of ATP2B4 mRNA]19228888
D014284TriiodothyronineTriiodothyronine results in increased expression of ATP2B4 mRNA19228888
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of ATP2B4 mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ATP2B4 mRNA21570461
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of ATP2B4 mRNA28065790
C024746tobacco tartobacco tar results in decreased expression of ATP2B4 mRNA19559774
D014212TretinoinTretinoin affects the expression of ATP2B4 mRNA18230668
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of ATP2B4 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2B4 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ATP2B4 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased methylation of ATP2B4 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of ATP2B4 mRNA19101580|2317975
D014638VanadatesVanadates results in increased expression of ATP2B4 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ATP2B4 gene25560391
D014750VincristineVincristine results in increased expression of ATP2B4 mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005388calcium-transporting ATPase activity-IBA21873635  
GO:0005388calcium-transporting ATPase activity-IMP8530416  
GO:0005388calcium-transporting ATPase activity-TAS-  
GO:0005515protein binding-IPI11591728  17242280  17689535  22084111  
GO:0005516calmodulin binding-IDA8530416  
GO:0005524ATP binding-IEA-  
GO:0017080sodium channel regulator activitycontributes_toISS-  
GO:0019829cation-transporting ATPase activity-IBA21873635  
GO:0019901protein kinase binding-IEA-  
GO:0030165PDZ domain binding-IBA21873635  
GO:0030346protein phosphatase 2B binding-IDA19287093  
GO:0036487nitric-oxide synthase inhibitor activity-IDA17242280  
GO:0036487nitric-oxide synthase inhibitor activitycontributes_toIDA11591728  
GO:0046872metal ion binding-IEA-  
GO:0050998nitric-oxide synthase binding-IPI11591728  
GO:0097110scaffold protein binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0003407neural retina development-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IMP19287093  
GO:0006874cellular calcium ion homeostasis-IBA21873635  
GO:0006874cellular calcium ion homeostasis-IC8530416  
GO:0006874cellular calcium ion homeostasis-IDA19278978  
GO:0006874cellular calcium ion homeostasis-ISS-  
GO:0007283spermatogenesis-IEA-  
GO:0010751negative regulation of nitric oxide mediated signal transduction-IDA19278978  
GO:0021766hippocampus development-IEA-  
GO:0030317flagellated sperm motility-ISS-  
GO:0033138positive regulation of peptidyl-serine phosphorylation-IDA19278978  
GO:0034220ion transmembrane transport-TAS-  
GO:0045019negative regulation of nitric oxide biosynthetic process-IDA11591728  19278978  
GO:0051001negative regulation of nitric-oxide synthase activity-IDA11591728  17242280  19278978  19287093  
GO:0051480regulation of cytosolic calcium ion concentration-IBA21873635  
GO:0051599response to hydrostatic pressure-IMP19287093  
GO:0070588calcium ion transmembrane transport-IMP8530416  
GO:0070885negative regulation of calcineurin-NFAT signaling cascade-IDA19287093  
GO:0071872cellular response to epinephrine stimulus-IDA19278978  
GO:0097553calcium ion transmembrane import into cytosol-IC8530416  
GO:0098703calcium ion import across plasma membrane-IC8530416  
GO:0098736negative regulation of the force of heart contraction-IDA17242280  
GO:0099132ATP hydrolysis coupled cation transmembrane transport-IEA-  
GO:0140199negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process-IDA17242280  
GO:1900082negative regulation of arginine catabolic process-IDA19278978  
GO:1901660calcium ion export-IEA-  
GO:1902083negative regulation of peptidyl-cysteine S-nitrosylation-NAS18591664  
GO:1902305regulation of sodium ion transmembrane transport-IC18591664  
GO:1902806regulation of cell cycle G1/S phase transition-IMP24448801  
GO:1903243negative regulation of cardiac muscle hypertrophy in response to stress-IMP19287093  
GO:1903249negative regulation of citrulline biosynthetic process-IDA19278978  
GO:1903779regulation of cardiac conduction-TAS-  
GO:2000481positive regulation of cAMP-dependent protein kinase activity-IDA19278978  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IDA-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-TAS2137451  
GO:0005901caveola-TAS11591728  
GO:0016020membrane-HDA19946888  
GO:0016020membrane-IDA8530416  
GO:0016323basolateral plasma membrane-IEA-  
GO:0030018Z disc-IDA19287093  
GO:0030315T-tubule-IDA19287093  
GO:0032991protein-containing complex-ISS-  
GO:0036126sperm flagellum-ISS-  
GO:0043005neuron projection-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
GO:0097228sperm principal piece-IEA-  
KEGG ID KEGG Term
hsa04020Calcium signaling pathway
hsa04970Salivary secretion
hsa04972Pancreatic secretion
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-397014Muscle contractionTAS
R-HSA-418346Platelet homeostasisTAS
R-HSA-418359Reduction of cytosolic Ca++ levelsTAS
R-HSA-418360Platelet calcium homeostasisTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5578775Ion homeostasisTAS
R-HSA-936837Ion transport by P-type ATPasesTAS
R-HSA-983712Ion channel transportTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal